Novo Nordisk Secures Global Rights to Experimental Obesity Pill Targeting GLP‑1 and GIP Receptors
Novo Nordisk has entered a partnership with Jiangsu Hengrui Pharmaceuticals to obtain a worldwide licence for the development and commercialization of HRS‑1596, an investigational oral obesity medication. The collaboration involves an upfront payment and a tiered royalty structure that rewards Hengrui on subsequent sales, positioning Novo as a strategic player in the emerging weekly‑dosed weight‑loss market.
Scientific Rationale
HRS‑1596 is a dual agonist of glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP) receptors. Activation of GLP‑1 receptors in the hypothalamus reduces appetite and delays gastric emptying, whereas GIP receptor engagement enhances insulin secretion and modulates energy expenditure. Preclinical data indicate that co‑stimulation of these pathways yields a synergistic effect on weight reduction, surpassing the modest benefit seen with monotherapy.
Unlike the once‑daily injectable GLP‑1 analogues currently on the market, HRS‑1596 is formulated for weekly oral dosing. The formulation employs a protected peptidomimetic core that resists gastrointestinal proteases and utilizes a self‑emulsifying delivery system to facilitate lymphatic uptake, thereby achieving therapeutic plasma concentrations with reduced dosing frequency.
Clinical Development Plan
The first‑in‑human phase I trial (NCT05432145) evaluated safety, tolerability, and pharmacokinetics in healthy volunteers. Results demonstrated a favorable safety profile, with transient gastrointestinal adverse events comparable to existing GLP‑1 agents. Pharmacodynamic markers, including plasma GLP‑1 and GIP levels, confirmed receptor engagement at the administered dose.
Phase II is slated to begin in Q3 2026, enrolling adults with a BMI ≥ 30 kg/m² or ≥ 27 kg/m² with a comorbidity. The primary endpoint will be the mean percentage change in body weight at 12 weeks. Secondary endpoints include changes in waist circumference, fasting glucose, lipid profile, and quality‑of‑life scores. The study design incorporates an adaptive randomization strategy to refine dose selection based on interim pharmacodynamic data.
Regulatory submission pathways are being prepared for the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Novo’s experience with its GLP‑1 products, such as semaglutide, will inform the anticipated regulatory dialogue, particularly concerning the demonstration of long‑term safety and efficacy in a broader patient population.
Market Implications
Obesity pharmacotherapy represents a growing therapeutic arena, with current approvals limited to once‑daily injections. A weekly oral formulation could dramatically improve adherence, a critical factor that has historically impeded the clinical impact of GLP‑1 agents. Novo’s acquisition of HRS‑1596 aligns with its strategic objective to broaden its obesity portfolio beyond its flagship semaglutide product, potentially capturing a sizable share of the projected U.S. and EU obesity treatment markets, which were valued at > $10 billion in 2025 and are projected to exceed $15 billion by 2030.
Regeneron and Biohaven Collaborate on FGFR3‑Directed Antibody‑Drug Conjugate Combined With Anti‑PD‑1 Therapy
Regeneron Pharmaceuticals and Biohaven Ltd. have formalized a clinical supply agreement to evaluate a first‑class antibody‑drug conjugate (ADC) targeting fibroblast growth factor receptor‑3 (FGFR3) in combination with an anti‑programmed death‑1 (PD‑1) checkpoint inhibitor. The program is scheduled for presentation at the 2026 EORTC‑NCI‑AACR symposium, reflecting an emerging strategy to integrate targeted oncology agents with immune checkpoint blockade.
Therapeutic Concept
FGFR3 is a tyrosine‑kinase receptor frequently amplified or mutated in bladder, breast, and other solid tumours. Current FGFR inhibitors, such as erdafitinib and rogaratinib, function as small‑molecule tyrosine‑kinase inhibitors (TKIs) that compete with ATP binding. However, resistance often develops through secondary mutations in the kinase domain or activation of compensatory pathways.
The new ADC comprises a humanized monoclonal antibody specific to FGFR3 conjugated to a DNA‑alkylating payload via a cleavable linker. Upon receptor binding, the complex is internalized and the linker is cleaved in the lysosomal environment, releasing the cytotoxic agent directly into the tumour cell. This approach offers several advantages:
- Tumour‑specific delivery: The ADC exploits the overexpression of FGFR3 on tumour cells, sparing normal tissues that express low receptor levels.
- Reduced systemic toxicity: The linker chemistry is engineered to prevent premature payload release, mitigating off‑target effects observed with small‑molecule TKIs.
- Bystander effect: The payload can diffuse into neighboring cells, potentially overcoming intratumour heterogeneity.
Combining the FGFR3‑ADC with an anti‑PD‑1 antibody (e.g., Regeneron’s own anti‑PD‑1 candidate) seeks to enhance tumour immunogenicity. The cytotoxic payload can induce immunogenic cell death, releasing neoantigens that prime T‑cell responses. Simultaneously, PD‑1 blockade removes inhibitory signals from T cells, potentially amplifying anti‑tumour immunity.
Clinical Development Status
The partnership will provide Biohaven with the ADC for in‑depth preclinical testing, including pharmacokinetics, biodistribution, and toxicity profiling. Once IND‑ready, a phase I/II dose‑escalation study will enroll patients with advanced, FGFR3‑positive tumours refractory to standard therapies. Primary endpoints will assess safety, tolerability, and maximum tolerated dose (MTD). Secondary endpoints will examine pharmacodynamic biomarkers (e.g., circulating tumour DNA, PD‑L1 expression) and early efficacy signals (objective response rate, duration of response).
The collaboration reflects a broader trend in oncology towards combination regimens that couple targeted agents with immunotherapies. Early data from other FGFR inhibitors combined with checkpoint blockade have shown mixed results, underscoring the need for agents with distinct mechanisms of action and improved tumour selectivity, as exemplified by the ADC approach.
Regulatory and Commercial Considerations
Regulatory agencies increasingly scrutinize combination therapies, especially when both agents are investigational. The agreement stipulates that regulatory filings will be coordinated, with the FDA and EMA reviewing the combined product under a joint clinical trial design. The partnership structure includes milestone‑based payments and a shared royalty framework, providing incentives for both parties to progress the ADC through late‑stage development.
From a market perspective, FGFR3‑positive tumours constitute a niche but significant cohort, with an estimated 5–10% of breast and urothelial cancers harboring actionable alterations. A highly selective, orally inactive ADC that synergizes with checkpoint inhibition could offer a differentiated therapeutic option in a field where resistance to TKIs remains a critical challenge.
